Aside from the tiny minority of people who can actually say what each of those initials stand for, we can divide the populace into two groups – those who specifically know that CRISPR is a tool used in gene editing and those who know (or figure) that it’s a highly promising but exceedingly complex technique […]
Articles
I’ve gotten a big pile of questions about the latest teaser pitch from Jeff Brown, who is now taking credit for the rise of the CRISPR stocks and sees another big surge coming. And for what it’s worth, he was one of the early newsletter guys promoting the three primary CRISPR stocks a few years […]
This article was originally published on November 5, 2018, we’re getting lots of questions so we’re popping it to the top of the page for you but it has not been updated or revised — the ad being covered appears to be almost identical to the ad that was running in the fall of 2018. […]
“This Wednesday, September 5 Tuesday, May 28, a group of scientists will take the stage at a prestigious medical conference… “And announce to the world the potential end of disease as we know it.” That’s the attention-getting part of Ray Blanco’s latest teaser ad for his FDA Trader newsletter that Gumshoe readers have been asking […]
Here’s a bit from the email that Matt McCall sent out introducing his lastest teaser ad: “When it comes down to it, there are really just three ways to get truly rich in the stock market. You can put thousands into the market every year, hold for decades, and retire with a fortune. You can […]
Matt McCall is pitching a “$200 into $1 million” stock idea as he tries to drum up subsribers for his NexGen Investor… and that sounds fun, right, owning a stock that goes to a million dollars per share? It probably won’t happen, of course, and I don’t know how many times it might have actually […]
This piece originally appeared as part of the Friday File for the Irregulars on July 28, but has now been unlocked for everyone. The company reported quarterly results about two weeks ago that were generally well received, and has otherwise gotten more positive press and analyst upgrades over the past month, and the shares are […]
The article below was originally published on November 27, 2017, when Jeff Brown’s ads promoting the “God Key” started to show up in our inboxes. It has not been updated or revised, but the new versions of the ad from Brown are very similar to the ones we covered in November, including the description of […]
Fear Of Missing Out is such a big deal that it gets its own acronym in my book (FOMO — and a clever FOMO-fueling website here), and it drives investors to take huge chances just so they don’t have to worry about missing a chance at stupendous gains. That’s what many newsletter ads use to […]
Bonner & Partners, which is yet another publisher subsidiary of Bill Bonner’s Agora empire, has a new teaser pitch out for Jeff Brown’s Exponential Tech Investor — and what caught the eye of Gumshoe readers was the headline, in the ad from Bonner’s Managing Director Amber Lee Mason, that promises huge gains from a “$39 […]
[ed. note: Michael Jorrin, who I call “Doc Gumshoe,” writes for us a couple times a month on health and medical issues — he is a longtime medical writer (not a doctor), he chooses his own topics, and his past articles can be found here.] Flub Number One is the puncture of the “female Viagra” […]
Today I’ve been asked about another urgent pitch from the Bonner & Partners crowd, and it’s so similar to one of their past ads that I thought I’d throw out the quick answer for you and let you chew on it a bit. The basic spiel is that there’s an IPO scheduled for Friday, and […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I would also appreciate the info. The initial 3 big guns were CRSP, EDIT, and NTLA. Second generation added BEAM, bu...
I have to agree with you deildog. On another front Jeff Brown Gave out a quick mover 2 days ago $EDIT, there are 2 other...
This Crisper for curing blindness is legit. NBC news had national news segment last week with a little girl getting to ...
Thanks for this report. There is a lot more to the technology than what I was thinking. I am invested in EDIT, and had a...
" I were dabbling in CRISPR I’d probably just buy a basket of the stocks (EDIT, NTLA, CRSP) and try to ignore them for...
Just saw it as well. He’s been on EDIT and NTLA in the past but not sure if there’s something new in regards to this...
We keep seeing this ad and getting more questions about it -- the ad hasn't changed in any big way that I've noticed, th...
I think you are looking for Intellia Therapeutics located in Cambridge, Mass. Stock symbol is NTLA....
I recommend looking at EDIT, CRSP, NTLA, MYGN, SGMO, and ILMN....
I would strongly check on these three gene editing companies: EDIT, CRSP, and NTLA. Other gene related companies that ...
ARK Genomic Revolution Multi-Sector ETF—ARKG This one has EDIT, CELG, NTLA, CRSP......
I think its cell data. https://www.investors.com/news/technology/crispr-gene-editing-biotech-companies/ https://mo...
I gave up on EDIT, NTLA, and CRSP and went with Illumina, Inc. (ILMN) which is similar but much less volatile. And ILMN ...
If you read all the way down to the end of Altucher's epic screed you see that he says you should buy all three: EDIT, N...
I have a really hard time with R&D companies or very early-stage clinical biotechs -- partly because it's an end market ...
I have bought some of Lichtenstein's lightening trades, I can say that ALGN was amazing 171% gain. Portola, took longe...